BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

200 related articles for article (PubMed ID: 24786129)

  • 1. Parosteal osteosarcoma.
    Hang JF; Chen PC
    Arch Pathol Lab Med; 2014 May; 138(5):694-9. PubMed ID: 24786129
    [TBL] [Abstract][Full Text] [Related]  

  • 2. MDM2 and CDK4 expression in periosteal osteosarcoma.
    Righi A; Gambarotti M; Benini S; Gamberi G; Cocchi S; Picci P; Bertoni F
    Hum Pathol; 2015 Apr; 46(4):549-53. PubMed ID: 25680902
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Value of MDM2, CDK4 and SATB2 immunohistochemistry in histologic diagnosis of low-grade osteosarcoma].
    Chen CY; Zhang HZ; Jiang ZM; Zhou J; Chen J; Liu L
    Zhonghua Bing Li Xue Za Zhi; 2016 Jun; 45(6):387-92. PubMed ID: 27256046
    [TBL] [Abstract][Full Text] [Related]  

  • 4. MDM2 and CDK4 immunohistochemistry is a valuable tool in the differential diagnosis of low-grade osteosarcomas and other primary fibro-osseous lesions of the bone.
    Dujardin F; Binh MB; Bouvier C; Gomez-Brouchet A; Larousserie F; Muret Ad; Louis-Brennetot C; Aurias A; Coindre JM; Guillou L; Pedeutour F; Duval H; Collin C; de Pinieux G
    Mod Pathol; 2011 May; 24(5):624-37. PubMed ID: 21336260
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immunohistochemical and FISH analysis of MDM2 and CDK4 in a dedifferentiated extraskeletal osteosarcoma arising in the vastus lateralis muscle: differential diagnosis and diagnostic algorithm.
    von Baer A; Ehrhardt A; Baumhoer D; Mayer-Steinacker R; Schultheiss M; Abdul-Nou T; Mentzel T; Fend F; Möller P; Jundt G; Barth TF
    Pathol Res Pract; 2014 Oct; 210(10):698-703. PubMed ID: 24974983
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical outcome of low-grade central osteosarcoma and role of CDK4 and MDM2 immunohistochemistry as a diagnostic adjunct.
    Jeon DG; Koh JS; Cho WH; Song WS; Kong CB; Cho SH; Lee SY; Lee SY
    J Orthop Sci; 2015 May; 20(3):529-37. PubMed ID: 25740728
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Characterization of the 12q15 MDM2 and 12q13-14 CDK4 amplicons and clinical correlations in osteosarcoma.
    Mejia-Guerrero S; Quejada M; Gokgoz N; Gill M; Parkes RK; Wunder JS; Andrulis IL
    Genes Chromosomes Cancer; 2010 Jun; 49(6):518-25. PubMed ID: 20196171
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immunohistochemical analysis of MDM2 and CDK4 distinguishes low-grade osteosarcoma from benign mimics.
    Yoshida A; Ushiku T; Motoi T; Shibata T; Beppu Y; Fukayama M; Tsuda H
    Mod Pathol; 2010 Sep; 23(9):1279-88. PubMed ID: 20601938
    [TBL] [Abstract][Full Text] [Related]  

  • 9. MDM2 and CDK4 immunohistochemical coexpression in high-grade osteosarcoma: correlation with a dedifferentiated subtype.
    Yoshida A; Ushiku T; Motoi T; Beppu Y; Fukayama M; Tsuda H; Shibata T
    Am J Surg Pathol; 2012 Mar; 36(3):423-31. PubMed ID: 22301501
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Giant cell rich osteosarcoma revisited-diagnostic criteria and histopathologic patterns, Ki67, CDK4, and MDM2 expression, changes in response to bisphosphonate and denosumab treatment.
    Chow LT
    Virchows Arch; 2016 Jun; 468(6):741-55. PubMed ID: 27003154
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Well-differentiated liposarcoma with low-grade osteosarcomatous component: an underrecognized variant.
    Yoshida A; Ushiku T; Motoi T; Shibata T; Fukayama M; Tsuda H
    Am J Surg Pathol; 2010 Sep; 34(9):1361-6. PubMed ID: 20697254
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The Utility of MDM2 and CDK4 Immunohistochemistry and MDM2 FISH in Craniofacial Osteosarcoma.
    Limbach AL; Lingen MW; McElherne J; Mashek H; Fitzpatrick C; Hyjek E; Mostofi R; Cipriani NA
    Head Neck Pathol; 2020 Dec; 14(4):889-898. PubMed ID: 32026294
    [TBL] [Abstract][Full Text] [Related]  

  • 13. 12q amplification defines a subtype of extraskeletal osteosarcoma with good prognosis that is the soft tissue homologue of parosteal osteosarcoma.
    Kyriazoglou AI; Vieira J; Dimitriadis E; Arnogiannaki N; Teixeira MR; Pandis N
    Cancer Genet; 2012 Jun; 205(6):332-6. PubMed ID: 22749040
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Activating GNAS mutations in parosteal osteosarcoma.
    Carter JM; Inwards CY; Jin L; Evers B; Wenger DE; Oliveira AM; Fritchie KJ
    Am J Surg Pathol; 2014 Mar; 38(3):402-9. PubMed ID: 24525511
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Imaging characteristics of primary osteosarcoma: nonconventional subtypes.
    Yarmish G; Klein MJ; Landa J; Lefkowitz RA; Hwang S
    Radiographics; 2010 Oct; 30(6):1653-72. PubMed ID: 21071381
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Gene amplification and tumor grading in parosteal osteosarcoma.
    Chen PC; Yen CC; Hung GY; Pan CC; Chen WM
    J Chin Med Assoc; 2019 Dec; 82(12):889-894. PubMed ID: 31634336
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Parosteal osteosarcoma: a case report.
    Chang LC; Chen BF; Wong LY
    Zhonghua Yi Xue Za Zhi (Taipei); 1991 Oct; 48(4):318-21. PubMed ID: 1659930
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Molecular analysis of p53, MDM2, and H-ras genes in osteosarcoma and malignant fibrous histiocytoma of bone in patients older than 40 years.
    Kawaguchi K; Oda Y; Sakamoto A; Saito T; Tamiya S; Iwamoto Y; Tsuneyoshi M
    Mod Pathol; 2002 Aug; 15(8):878-88. PubMed ID: 12181274
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Diagnosis and treatment of low-grade osteosarcoma: experience with nine cases.
    Hayashi K; Tsuchiya H; Yamamoto N; Shirai T; Nishida H; Takeuchi A; Kimura H; Miwa S; Inatani H; Okamoto H; Yamada S; Ikeda H; Sawada-Kitamura S; Nojima T; Ooi A; Otsuka T
    Int J Clin Oncol; 2014 Aug; 19(4):731-8. PubMed ID: 23881556
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Pathomorphology of parosteal osteosarcoma. Experience with 125 cases in the Hamburg Register of Bone Tumors].
    Delling G; Werner M
    Orthopade; 2003 Jan; 32(1):74-81. PubMed ID: 12557089
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.